The combined influence of oral contraceptives and human papillomavirus virus on cutaneous squamous cell carcinoma

Clinical Medicine Insights: Oncology

Volumn 5, Issue , 2011, Pages 55-75

  Efird, Jimmy T ^a   Toland, Amanda E ^b   Lea, C Suzanne ^a   Phillips, Christopher J ^c  

^a EAST CAROLINA UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

Cutaneous squamous cell carcinoma; Human papillomavirus virus; Oral contraceptives

Indexed keywords

ESTRADIOL; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROTEIN E6; PROTEIN E7; PROTEIN P53; VIRUS DNA;

CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CAUSAL ATTRIBUTION; DISEASE ASSOCIATION; DRUG USE; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE MUTATION; GRAFT RECIPIENT; HORMONE ACTION; HUMAN; NONHUMAN; ORGAN TRANSPLANTATION; PAPILLOMAVIRUS INFECTION; PERSISTENT VIRUS INFECTION; REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; VIRAL CLEARANCE; VIRUS CLASSIFICATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 79958033270     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6905     Document Type: Review

References (349)

1. Johnson T, Rowe D, Nelson B, Swanson N. Squamous cell carcinoma of the skin (excluding lip and oral mucosa). J Am Acad Dermatol. 1992;26:467-484.
2. Barksdale S, O'Connor N, Barnhill R. Prognostic factors for cutaneous squamous cell and basal cell carcinoma. Determinants of risk of recurrence, metastasis, and development of subsequent skin cancers. Surg Oncol Clin N Am. 1997;6:625-638.
3. Preston D, Stern R. Nonmelanoma cancers of the skin. N Engl J Med. 1992;327:1649-1662.
4. Roth J, Granick M. Squamous cell and adnexal carcinomas of the skin. Clin Plast Surg. 1997;24:687-703.
5. Alam M, Caldwell J, Eliezri Y. Human papillomavirus-associated digital squamous cell carcinoma literature review and report of 21 new cases. J Am Acad Dermatol. 2003;48:385-393.
6. Weinberg A, Ogle C, Shim E. Metastic cutaneous squamous cell carcinoma: an update. Dermatol Surg. 2007;33:885-899.
7. Rowe D, Carroll R, Day C. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip: implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976-990.
8. Penn I. Tumors of the immunocompromised patient. Ann Rev Med. 1988;39:63-73.
9. Maize J. Skin cancer in immunosuppressed patients. JAMA. 1977;237: 1857-1858.
10. Adamson R, Obispo E, Dychter S, et al. High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study. Tranplant Proc. 1998;30:1124-1126.
11. Euvrard S, Kanitakis J, Claudy A. Medical progress: skin cancers after organ transplantation. N Eng J Med. 2003;348:1681-1691.
12. Gupta A, Cardella C, Haberman H. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol. 1986;122:1288-1293.
13. Smith K, Hamza S, Skelton H. Histologic features in primary cutaneous squamous cell carcinomas in immunocompromised patients focusing on organ transplant patients. Dermatol Surg. 200;30:634-641.
14. Kinlen L. Immunosuppression and cancer. IARC Sci Publ. 1992;116: 237-253.
15. Webb M, Compton F, Andrews P, Koffman C. Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Trans Proc. 1997;29:828-830.
16. Ulrich C, Schmook T, Sachse M, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. Dermatol Surg. 2004;30:622-627.
17. Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E. Importance of human papillomaviruses for the development of skin cancer. Cancer Detect Prev. 2001;25:533-547.
18. Martin H, Strong E, Spiro R. Radiation-induced skin cancer of the head and neck. Cancer. 1970;25:61-71.
19. Nguyen P, Vin-Christian K, Ming M, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol. 2002;138:758-763.
20. Overly W, Jakubek D. Multiple squamous cell carcinoma and human immunodeficiency virus infection. Ann Inter Med. 1987;106:334.
21. Palefsky J, Rubin M. The epidemiology of anal human papillomavirus and related neoplasia. Obstet Gynecol Clin N Am. 2009;36:187-200.
22. Strom S, Yamamura Y. Epidemiology of nonmelanoma skin cancer. Clin Plast Surg. 1997;24:627-636.
23. Gloster H, Brodland D. The epidemiology of skin cancer. Dermatol Surg. 1996;22:217-226.
24. Halder R, Bang K. Skin cancer in blacks in the United States. Dermatol Clin. 1988;6:397-405.
25. Halder R, Bridgeman-Shah S. Skin cancer in African Americans. Cancer. 1995;75:667-673.
26. Isaacson C. Cancer of the skin in urban blacks of South Africa. Br J Dermatol. 1979;100:47-350.
27. Fleming I, Barnawell J, Burlison P, Rankin J. Skin Cancer in black patients. Cancer. 1975;35:600-605.
28. Oettle A. Skin cancer in Africa. NCI Mongr. 1963;10:197-214.
29. Rippey J, Schmaman A. Skin tumours of Africans. In: Marshall J, editor. Essays on Tropical Dermatology. Amsterdam: Excerpta Medica; 1972;2:99-115.
30. Ishikawa N, Tanabe K, Tokumoto T, et al. Clinical study of malignancies after renal transplantation and impact of routine screening for early detection: a single center experience. Transplant Proc. 2000;32:1907-10.
31. Polednak A. Racial & Ethnic Differences in Disease. NewYork: Oxford University Press; 1989.
32. Lee T, Lee A, Shi W. HLA-A, -B, -DR, -DQ antigens in black North Americans. Tissue Antigens. 1991;7:9-83.
33. Fraser P, Moore B, Stein R, et al. Complotypes in individuals of African origin: frequencies and possible extended MHC haplotypes. Immunogenetics. 1990;31:89-93.
34. Czarnecki D, Watkins F, Leahy S, et al. Skin cancers and HLA frequencies in renal transplant recipients. Dermatology. 1992;185:9-11.
35. World Health Organization, International Agency for Research on Cancer. Solar and ultraviolet radiation. IARC Monogr Eval Carcinog Risk Hum. 1992;55:1-316.
36. Young C. Solar ultraviolet radiation and skin cancer. Occup Med. 2009;59:82-88.
37. Gallagher R, Hill G, Bajdik C, et al. Sunlight exposure, pigmentation factors, and risk of nonmelanocytic skin cancer. II. Squamous cell carcinoma. Arch Dermatol. 1995;131:164-169.
38. Aubry F, MacGibbon B. Risk factors of squamous cell carcinoma of the skin. A case-control study in the Montreal region. Cancer. 1985;55:907-911.
39. Giles G, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J. 1988;296:13-17.
40. Green A, Battistutta D. Incidence and determinants of skin cancer in a highrisk Australian population. Int J Cancer. 1990;46:356-361.
41. English D, Armstrong B, Kricker A, Winter M, Heenan P, Randell P. Demographic characteristics, pigmentary and cutaneous risk factors for squamous cell carcinoma of the skin: a case-control study. Int J Cancer. 1998;76:628-634.
42. Asgari M, Efird J, Warton E, Friedman G. Potential risk factors for cutaneous squamous cell carcinoma include oral contraceptives: results of a nested case-control study. Int J Env Res Public Health. 2010;7:427-442.
43. Grodstein F, Speizer F, Hunter D. A prospective study of incident squamous cell carcinoma of the skin in the Nurses' Health Study. J Natl Cancer Inst. 1995;87:1061-1066.
44. Kricker A, Armstrong B, English D, Heenan P. Pigmentary and cutaneous risk factors for non-melanocytic skin cnacer-a case-control study. Int J Cancer. 1991;48:650-662.
45. Murphy G. Ultraviolet radiation and immunosuppression. Br J Dermatol. 2009;161:90-95.
46. Nishigori C, Yarosh D, Donawho C, Kripke M. The immune system in ultraviolet carcinogenesis. J Investig Dermatol Symp Proc. 1996;1:143-146.
47. Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur J Dermatol. 2003;13:515-523.
48. Beissert S, Schwarz T. Mechanisms involved in ultraviolet light induced immunosuppression. J Investig Dermatol Symp Proc. 1999;4:61-64.
49. De Gruijl F. Photocarcinogenesis: UVA vs. UVB radiation. Skin Pharmacol Appl Skin Physiol. 2002;15:316-320.
50. Findlay G. Ultra-violet light and skin cancer. Lancet. 1928;2:1070-1073.
51. Winkelmann R, Zollman P, Baldes E. Squamous cell carcinoma produced by ultraviolet light in hairless mice. J Invest Dermatol. 1963;40:217-224.
52. Kripke M. Immunology and photocarcinogenesis. New light on an old problem. J Am Acad Dermatol. 1986;14:149-155.
53. Beissert S, Schwarz T. Ultraviolet-induced immunosuppression: implications for photocarcinogenesis. Cancer Treat Res. 2009;146:109-121.
54. Weaver S, Kelly A, Lopansri S. Dysplastic epidermal keratosis in a black woman. Arch Dermatol. 1981;117:800-803.
55. Amonette R, Kaplan R. Squamous-cell and basal-cell carcinomas in black patients. J Dermatol Surg. 1976;2:158-161.
56. White J, Strudwick W, Ricketts W, Sampson C. Cancer of the skin in Negroes: A review of 31 cases. JAMA. 1961;178:845-847.
57. Levi F, La Vecchia C, Te V, Mezzanotte F. Descriptive epidemiology of skin cancer in the Swiss Canton of Vaud. Int J Cancer. 1988;42:811-816.
58. Stern R. The mysteries of geographic variability in nonmelanoma skin cancer incidence. Arch Dermatol. 1999;135:843-844.
59. Karagas M, Nelson H, Zens M, et al. Squamous cell and basal cell carcinoma of the skin in relation to radiation therapy and potential modification of risk by sun exposure. Epidemiology. 2007;18:776-784.
60. Masini C, Fuchs P, Gabrielli F, et al. Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent\ individuals. Arch Dermatol. 2003;139:890-894.
61. Eatough J, Henshaw D. The theoretical risk of non-melanoma skin cancer from environmental radon exposure. J Radiol Prot. 1995;15:45-51.
62. Rintala A. Radiation cancer. J Plast Surg Hand Surg. 1967;1:5-11.
63. Shore R. Overview of radiation-induced skin cancer in humans. Int J Radiat Biol. 1990;57:809-827.
64. Wang J, Inskip P, Boice J, Li B, Zhang J, Fraumeni J. Cancer incidence among medical diagnotic x-ray workers in China, 1950-1985. Int J Cancer. 1990;45:889-895.
65. Sadamori N, Mine M, Honda T. Incidence of skin cancer among Nagasaki atomic bomb survivors. J Radiat Res. 1991;32:217-225.
66. Van Vloten W, Hermans J, van Daal W. Radiation-induced skin cancer and radiodermatitis of the head and neck. Cancer. 1987;59:411-414.
67. Frieben E. Demonstration eines Cancroids des rechten Handrückens das sich nach langdauernder Einwirkung von Röntgenstrahlen entwickelt hatte. Forschr Geb Röntgenstr. 1902;6:106-111.
68. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001; 344: 975-983.
69. Gallagher R, Bajdik C, Fincham S, et al. Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev. 1996; 5: 419-424.
70. Purdie K, Surentheran T, Sterling J, et al. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol. 2005; 125: 98-107.
71. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomavirus in transplant-associated skin cancers. Dermatol Surg. 2004; 30: 604-609.
72. Schwartz R, Stoll H. Chapter 80: Squamous cell carcinoma. In: Freedberg I, Eisen A, Wolff K, Austen K, Goldsmith L, Katz S, Fitzpatrick T, editors. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York: McGraw-Hill; 1999.
73. Scotto J, Fears T, Kraemer K, Fraumeni J. Chapter 60: Nonmelanoma skin cancer. In: Schottenfeld D, Fraumeni J, editors. Cancer Epidemiology and Prevention. 2nd ed. New York: Oxford University Press; 1996: 1313-1326.
74. Pfister H. Chapter 8: Human papillomavirus and skin cancer. J Natl Cancer Inst Monogr. 2003; 31: 52-56.
75. Sterling J. Human papillomaviruses and skin cancer. J Clin Virol. 2005; 32S: S67-S71.
76. De Villiers E. Human papillomavirus infections in skin cancers. Biomed & Pharmacother. 1998;52:26-33.
77. De Villiers E, Ruhland A, Šekarić P. Human papillomaviruses in non-melanoma skin cancer. Semin Cancer Biol. 1999;9:413-422.
78. Harwood C, McGregor J, Proby C, Breuer J. Human papillomavirus and the development of non-melanoma skin cancer. J Clin Pathol. 1999;52:249-253.
79. Hemminki K, Li X. Level of education and the risk of cancer in Sweden. Cancer. Epidemiol Biomarkers Prev. 2003;12:796-802.
80. Hemminki K, Zhang H, Czene K. Socioeconomic factors in cancer in Sweden. Int J Cancer. 2003;105:692-700.
81. Glass A, Hoover R. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989;262:2097-2100.
82. Gallagher R, Ma B, McLean D, et al. Trends in basal cell carcinoma, and melanoma of the skin from 1973 through 1987. J Am Acad Dermatol. 1990;23:413-421.
83. Gray D, Suman V, Su W, Clay R, Harmsen W, Roenigk R. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol. 1997;133:735-740.
84. Wassberg C, Thörn M, Johansson A, Bergström R, Berne B, Ringborg U. Increasing incidence rates of squamous cell carcinoma of the skin in Sweden. Acta Derm Venereol. 2001;81:268-272.
85. Hemminki K, Zhang H, Czene K. Time trends and familial risks in squamous cell carcinoma of the skin. Arch Dermatol. 2003;139:885-889.
86. Coebergh J, Neumann H, Vrints L, van der Heijden L, Meijer W, Verhagen- Teulings M. Trends in the incidence of non-melanoma skin cancer in the SE Netherlands 1975-1988: a registry-based study. Br J Dermatol. 1991;125:353-359.
87. Staples M, Marks R, Giles G. Trends in the incidence of non-melanocytic skin cancer (NMSC) treated in Australia 1985-1995: are primary prevention programs starting to have an effect? Int J Cancer. 1998;78:144-148.
88. Kripke M. Impact of ozone depletion on skin cancers. J Dermatol Surg Oncol. 1988;14:853-857.
89. Henriksen T, Dahlback A, Larsen S, Moan J. Ultraviolet-radiation and skin cancer. Effect of an ozone layer depletion. Photochem Photobiol. 1990;51:579-582.
90. Abarca J, Casiccia C. Skin cancer and ultraviolet-B radiation under the Antarctic ozone hole: southern Chile, 1987-2000. Photodermatol Photoimmunol Photomed. 2002;18:294-302.
91. Amron D, Moy R. Stratospheric ozone depletion and its relationship to skin cancer. J Dermatol Surg Oncol. 1991;17:370-372.
92. Efird J, Friedman G, Habel L, Tekawa I, Nelson L. Risk of subsequent cancer following invasive or in situ squamous cell skin cancer. Ann Epidemiol. 2002;12:469-475.
93. Karagas M, Greenberg E, Mott L, Baron J, Ernster V. Occurrence of other cancers among patients with prior basal cell and squamous cell skin cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:157-161.
94. Frisch M, Melbye M. New primary cancers after squamous cell skin cancer. Am J Epidemiol. 1995;141:916-922.
95. Kahn H, Tatham L, Patel A, Thun M, Heath C. Increased cancer mortality following a history of nonmelanoma skin cancer. JAMA. 1998;280:910-912.
96. Levi R, Randimbison L, La Vecchia C, Erler G, Te V. Incidence of invasive cancers following squamous cell skin cancer. Am J Epidemiol. 1997;146:734-739.
97. Adami J, Frisch M, Yuen J, Glimelius B, Melbye M. Evidence of an association between non-Hodgkin's lymphoma and skin cancer. Br Med J. 1995;310:1491-1495.
98. Levi F, Randimbison L, Te V, Conconi M, La Vecchia C. Risk of prostate, breast and colorectal cancer after skin cancer diagnosis. Int J Cancer. 2008;123:2899-2901.
99. Maitra S, Gallo H, Rowland-Payne C, Robinson D, Møller H. Second primary cancers in patients with squamous cell carcinoma of the skin. Br J Cancer. 2005;92:570-571.
100. Toro J, Blake P, Björkholm M, Kristinsson S, Wang Z, Landgren O. Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. Haematologica. 2009;94:1460-1464.
101. Chen J, Ruczinski I, Jorgensen T, et al. Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst. 2008;100:1215-1222.
102. Rosenberg C, Khandekar J, Greenland P, Rodabough R, McTiernan A. Cutaneous melanoma in postmenopausal women after nonmelanoma skin carcinoma. The Women's Health Initiative Observational Study. Cancer. 2006;106:654-663.
103. Rosenberg C, Greenland P, Khandekar J, Loar A, Ascensao J, Lopez A. Association of nonmelanoma skin cancer with second malignancy. The Women's Health Initiative Observational Study. Cancer. 2004;100:130-138.
104. Nugent Z, Demers A, Wiseman M, Mihalcioiu C, Kliewer E. Risk of second primary cancer and death following a diagnosis of nonmelanoma skin cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:2584-2590.
105. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T. Secondary primary cancers in patients with squamous cell carcinoma of the skin: a population- based study in Sweden. Int J Cancer. 1999;80:511-515.
106. Troyanova P, Danon S, Ivanova T. Nonmelanoma skin cancers and risk of subsequent malignancies: a cancer registry-based study in Bulgaria. Neoplasma. 2002;49:81-85.
107. Hjalgrim H, Frisch M, Strom H, Glimelius B, Pedersen J, Melbye M. Nonmelanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkins lymphoma. Int J Cancer. 2000;85:639-642.
108. Marcil I, Stern R. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524-1530.
109. Graells J. The risk and risk factors of a second non-melanoma skin cancer: a study in a mediterranean population. J Eur Acad Dermatol Venereol. 2004;18:142-147.
110. Cantwell M, Murray L, Catney D, et al. Secondary primary cancers in patients with skin cancer: a population-based study in Northern Ireland. Br J Cancer. 2009;100:174-177.
111. Crocetti E, Buiatti E, Falini P, the Italian Multiple Primary Cancer Working Group. Multiple primary cancer incidence in Italy. Eur J Cancer. 2001;37:2449-2456.
112. Hemminki K, Jiang Y, Dong C. Second primary cancers after anogenital, skin, oral, esophageal and rectal cancers: etiological links? Int J Cancer. 2001;93:294-298.
113. Hemminki K, Dong C. Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol. 2000;136:647-651.
114. Hemminki K, Dong C. Primary cancers following squamous cell carcinoma of the skin suggest involvement of Epstein-Barr virus. Epidemiology. 2000;11:94.
115. Jæger A, Gramkow A, Hjalgrim H, Melbye M, Frisch M. Bowen disease and risk of subsequent malignant neoplasms-a population-based cohort study of 1147 patients. Arch Dermatol. 1999;135:790-793.
116. Marghoob A, Slade J, Salopek T, Kopf A, Bart R, Rigel D. Basal cell and squamous cell carcinomas are important risk factors for cutaneous malignant melanoma. Screening implications. Cancer. 1995;75:707-714.
117. Applebaum K, Nelson H, Zens M, Stukel T, Spencer S, Karagas M. Oral contraceptives: a risk factor for squamous cell carcinoma? J Invest Dermatol. 2009;129:2760-2765.
118. Muñoz N, Kjaer S, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital disease in young women. J Natl Cancer Inst. 2010;102:325-339.
119. Cavalieri E, Frenkel K, Liehr J, Rogan E, Roy D. Chapter 4: estrogens as endogenous genotoxic agents-DNA adducts and mutations. J Natl Cancer Inst. 2000;27:75-93.
120. Cogliano V, Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F; for the WHO International Agency for Research on Cancer. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552-553.
121. World Health Organization, International Agency for Research on Cancer. Combined estrogen-progestogen contraceptives and combined estrogenprogestogen menopausal therapy. IARC Monogr Eval Carcinog Risk Hum. 2007;91:1-528.
122. World Health Organization, International Agency for Research on Cancer. Hormonal contraception and post-menopausal hormonal therapy. IARC Monogr Eval Carcinog Risk Hum. 1999;72:1-660.
123. Grimes D. Neoplastic effects of oral contraceptives. Int J Fertil. 1991;36:19-24.
124. Huber J, Bentz E, Ott J, Tempfer C. Non-contraceptive benefits of oral contraceptives. Expert Opin Parmacother. 2008;9:2317-2325.
125. Cibula D, Gompel A, Mueck A, et al. Hormonal contraception and risk of cancer. Hum Reprod Update. 2010;16:631-650.
126. Dolle J, Daling J, White E, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18:1157-1166.
127. Dossus L, Allen N, Kaaks R, et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2010;127:442-451.
128. Vessey M, Painter R, Powell J. Skin disorders in relation to oral contraception and other factors including age, social class, smoking and body mass index. Findings in a large cohort study. Br J Dermatol. 2000;143:815-820.
129. Cousins R. Annotated bibliography of some papers on combining significances or p-values. 20 Dec 2008, p. 1-15. Available at http://arxiv.org/abs/0705.2209. Accessed 29 January, 2011.
130. Fleiss J, Gross A. Meta-analsis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol. 1991;44:127-139.
131. Braendle W, Kuhl H, Mueck A, et al. Does hormonal contraception increase the risk for tumors? Ther Umsch. 2009;66:129-135.
132. Edgren R. Oral contraceptives and cancer. Int J Fertil. 1991;36:37-50.
133. Gates M, Tworoger S, Eliassen A, Missmer S, Hankinson S. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2010;19:1033-1041.
134. Miller C, Murtagh J. Combined oral contraception. Aust Fam Physician 1992;21:1787-1788.
135. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Beral V, Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer from 87303 controls. Lancet. 2008;371:303-314.
136. Satterthwaite A. A comparative study of low dosage oral contraceptives. Appl Ther. 1964;6:410-418.
137. Fraser D, Padwick M, Whitehead M, Coffer A, King R. Presence of an oestradiol receptor-related protein in the skin: changes during the normal menstrual cycle. Br J Obstet Gynaecol. 1991;98:1277-1282.
138. Kousteni S, Bellido T, Plotkin L, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104:719-730.
139. Rogers G, Flowers J, Pollack S, McCarty K. Determination of sex steroid receptor in human basal cell carcinoma. J Am Acad Dermatol. 1988;18:1039-1043.
140. Leslie K, Espey E. Oral contraceptives and skin cancer: is there a link? Am J Clin Dermatol. 2005;6:349-355.
141. Liu W, Konduri S, Bansal S, et al. Estrogen receptor-α binds p53 tumor suppressor protein directly and represses its function. J Biol Chem. 2006;281:9837-9840.
142. Mancuso M, Gallo D, Leonardi S, et al. Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer. Carcinogenesis. 2009;30:340-347.
143. Schmeink C, Lenselink C, Bekkers R. Use of oral contraceptives and increased risk of cervical cancer. Ned Tijdschr Geneeskd. 2008;152:1717-1718.
144. Bravo I, de Sanjosé S, Gottschling M. The clinical importance of understanding the evolution of papillomaviruses. Trends Microbiol. 2010;18:432-438.
145. Coggin J, Zur Hausen H. Workshop on papillomaviruses and cancer. Cancer Res. 1979;39:545-546.
146. De Villiers E, Fauquet C, Broker T, Bernard H, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
147. Bernard H. The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. J Clin Virol. 2005;32S:S1-S6.
148. Forslund O. Genetic diversity of cutaneous human papillomaviruses. J Gen Virol. 2007;88:2662-2669.
149. Plasmeijer E, Neale R, de Koning M, et al. Persistence of betapapillomavirus infections as a risk factor for actinic keratoses, precursor to cutaneous squamous cell carcinoma. Cancer Res. 2009;69:8926-8931.
150. De Villiers E. Heterogeneity of the human papillomavirus group. J Virol. 1989;63:4898-4903.
151. Beard J, Rous P. A virus-induced mamalian growth with the characters of a tumor (the Shope rabbit papilloma). II. Experimental alterations of the growth of the skin: morphological considerations: the phenomena of retrogression. J Exp Med. 1934;60:723-740.
152. Rous R, Beard J. The progression to carcinoma of virus-induced rabbit papillomas (Shope). J Exp Med. 1935;62:523-548.
153. Mitsuishi T, Sata T, Matsukura T, Iwasaki T, Kawashima M. The presence of mucosal human papillomavirus in Bowen's disease of the hands. Cancer. 1997;79:1911-1917.
154. Forslund O, Nordin P, Hansson B. Mucosal human papillomavirus types in squamous cell carcinomas of the uterine cervix and subsequently on fingers. Br J Dermatol. 2000;142:1148-1153.
155. Sánchez-Lanier M, Triplett C, Campion M. Possible role for human papillomavirus 16 in squamous cell carcinoma of the finger. J Med Virol. 1994;44:369-378.
156. Sonnex C, Strauss J, Gray J. Detection of human papillomavirus DNA on the fingers of patients with genital warts. Sex Transm Inf. 1999;75:317-319.
157. Moy R, Eliezri Y, Nuovo G, Zitelli J, Bennett R, Silverstein S. Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. JAMA. 1989;261:2669-2673.
158. Kreuter A, Brockmeyer N, Pfister H, Altmeyer P, Wieland U; for the Competence Network HIV/AIDS. Humanpapillomavirus type 26-associated periungual squamous cell carcinoma in situ in a HIV-infected patient with concomitant penile and anal intraepithelial neoplasia. J Am Acad Dermatol. 2005;53:737-739.
159. Eliezri Y, Silverstein S, Nuovo G. Occurence of human papillomavirus type 16 DNA in cutaneous squamos and basal cell neoplasms. J Am Acad Dermatol. 1990;23:836-842.
160. Stone M, Noonan C, Tschen J, Bruce S. Bowen's disease of the feet. Presence of human papillomavirus 16 DNA in tumor tissue. Arch Dermatol. 1987;123:1517-1520.
161. Forslund O, Nordin P, Andersson K, Stenquist B, Hansson B. DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen disease on fingers and in archival samples from genital dysplasia. Br J Dermatol. 1997;136:678-682.
162. Nordin P, Stenquist B, Hansson B. Joint occurence of human papillomavirus type 16 DNA in Bowen's disease on a finger and in dysplasia of the vulva and the uterine cervix. Br J Dermatol. 1994;131:740.
163. Kettler A, Rutledge M, Tschen J, Buffone G. Detection of human papillomavirus in nongenital Bowen's disease by in situ DNA hybridization. Arch Dermatol. 1990;126:777-781.
164. Goshima J, Hara H, Honda A, Suzuki H, Matsukura T. Detection of human papillomavirus type 16 in Bowen's disease of the web-space of the foot. Acta Derm Venereol. 2005;85:188-189.
165. Ashinoff R, Li J, Jacobson M, Friedman-Kien A, Geronemus R. Detection of human papillomavirus DNA in squamous cell carcinoma of the nail bed and finger determined by polymerase chain reaction. Arch Dermatol. 1991;127:1813-1888.
166. Moy R, Quan M. The presence of human papillomavirus type 16 in squamous cell carcinoma of the proximal finger and reconstruction with a bilobed transposition flap. J Dermatol Surg Oncol. 1991;17:171-175.
167. Clavel C, Huu V, Durlach A, Birembaut P, Bernard P, Derancourt C. Mucosal oncogenic human papillomaviruses and extragenital Bowen disease. Cancer. 1999;86:282-287.
168. Sau P, McMarlin S, Sperling L, Katz R. Bowen's disease of the nail bed and periungual area. A clinicopathologic analysis of seven cases. Arch Dermatol. 1994;13:204-209.
169. Rüdlinger R, Grob R, Yu Y, Schnyder U. Human papillomavirus-35- Positive bowenoid papulosis of the anogenital area and concurrent human papillomavirus-35-positive verruca with bowenoid dysplasia of the periungual area. Arch Dermatol. 1989;125:655-659.
170. McGrae J, Greer C, Manos M. Multiple Bowen's disease of the fingers associated with human papilloma virus type 16. Int J Dermatol. 1993;32:104-107.
171. Gordon M, Palusci V. Human papillomavirus type 16 periungual carcinoma. JAMA. 1989;262:3407-408.
172. De Dobbeleer G, André J, Laporte M, Schroeder F, Peny M, Scarcériaux B, Noël J. Human papillomavirus type 6/11 and 16 in periungual squamouscarcinoma in situ. Eur J Dermatol. 1993;3:12-14.
173. Guitart J, Bergfeld W, Tuthill R, Tubbs R, Zienowicz R, Fleegler E. Squamous cell carcinoma of the nail bed: a clinopathological study of 12 cases. Br J Dermatol. 1990;123:215-222.
174. Ekström J, Forslund O, Dillner J. Three novel papillomaviruses (HPV 112 and HPV114) and their presence in cutaneous and mucosal samples. Virology. 2010;397:331-336.
175. Feltkamp M, de Koning M, Bouwes Bavinck J, ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol. 2008;43:353-360.
176. Muller H, Bauch C. When do sexual partnerships need to be accounted for in transmission models of human papillomavirus? Int J Environ Res Public Health. 2010;7:635-650.
177. Antonsson A, Forslund O, Ekberg H, Sterner G, Hansson B. The ubiquity and impressive genomic diversity of human skin papillomaviruses suggest a commensalic nature of these viruses. J Virol. 2000;74:11636-11641.
178. Astori G, Lavergne D, Benton C, Höckmayr B, Egawa E, Garbe C, de Villiers E. Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. J Invest Dermatol. 1998;110:752-755.
179. De Koning M, Struijk L, Bavinck J, et al. Betapapillomaviruses frequently persist in the skin of healthy individuals. J Gen Virol. 2007;88:1489-1495.
180. Pfister H, Fuchs P, Majewski S, Jablonska S, Pniewska I, Malejczyk M. High prevalence of epidermodysplasia verruciformis-associated human papillomavirus DNA in actinic keratoses of the immunocompetent populaiton. Arch Dermatol Res. 2003;295:273-279.
181. Zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-F78.
182. McKaig R, Baric R, Olshan A. Human papillomavirus and head and neck cancer: pidemiology and molecular biology. Head Neck. 1998;20:250-225.
183. Maden C, Beckmann A, Thomas D, et al. Human papillomavirus, herpes implex viruses, and the risk of oral cancer in men. Am J Epidemiol. 1992;135:1093-1102.
184. Caruana S, Zwiebel N, Cocker R, McCormick S, Eberle R, Lazarus P. p53 lteration and human papillomavirus infection in paranasal sinus cancer. Cancer. 1997;79:1320-1328
185. Inaba Y, Egawa K, Yoshimura K, Ono T. Demonstration of human pillomavirus type 1 DNA in a wart with Bowenoid histologic changes. Am J Dermatopathol. 1993;15:172-175.
186. Noel J, Detremmerie O, Peny M, et al. Transformation of common warts into squamous cell carcinoma on sun-exposed areas in an immunosuppressed patient. Dermatology. 1994;189:308-311.
187. Noel J, Peny M, Detremmerie O, et al. Demonstration of human papillomavirus type 2 in a verrucous carcinoma of the foot. Dermatology. 1993;187:58-61.
188. Burk R, Kadish A. Treasure hunt for human papillomaviruses in nonmelanoma skin cancers. J Natl Cancer Inst. 1996;88:781-782.
189. Shamanin V, Zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst. 1996;88:802-811.
190. Harwood C, Spink P, Surentheran T, et al. Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol. 1999;37:3545-3555.
191. Soler C, Allibert P, Chardonnet Y, Cros P, Mandrand B, Thivolet J. Detection of human papillomavirus types 6, 11, 16 and 18 in mucosal and cutaneous lesions by the multiplex polymerase chain reaction. J Virol Methods. 1991;35:143-157.
192. Soler C, Chardonnet Y, Allibert P, Euvrard S, Schmitt D, Mandrand B. Detection of mucosal human papillomavirus types 6/11 in cutaneous lesions from transplant recipients. J Invest Dermatol. 1993;101:286-291.
193. Kessis T, Slebos R, Nelson W, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A. 1993;90:3988-3992.
194. Werness B, Levine A, Howley P. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science. 1990;248:76-79.
195. Scheffner M, Werness B, Huibregtse J, Levine A, Howley P. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;21:1129-1136.
196. Steenbergen R, Hermsen M, Walboomers J, et al. Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res. 1995;55:5465-5471.
197. Park N, Gujuluva C, Baek J, Cherrick H, Shin K, Min B. Combined oral carcinogenicity of HPV-16 and benzo(a)pyrene: an in vitro multistep carcinogenesis model. Oncogene. 1995;10:2145-2153.
198. Iglesias M, Yen K, Gaiotti D, Hildesheim A, Stoler M, Woodworth C. Human papillomavirus type 16 E7 protein sensitizes cervical keratinocytes to apoptosis and release of interleukin-1α. Oncogene. 1998;17:1195-1205.
199. Iftner T, Bierfelder S, Csapo Z, Pfister H. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol. 1988;62:3655-3661.
200. Woodworth C, Doniger J, DiPaolo J. Immortalization of human foreskin keratinocytes by various human papillomavirus DNAs corresponds to their association with cervical carcinoma. J Virol. 1989;63:159-164.
201. Kiyono T, Hiraiwa A, Ishibashi M. Differences in transforming activity and coded amino acid sequence among E6 genes of several papillomaviruses associated with epidermodysplasia verruciformis. Virology. 1992;186:28-639.
202. Thomas M, Pim D, Banks L. The role of E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 1999;18:7690-7700.
203. Jackson S, Storey A. E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage. Oncogene. 2000;19:592-598.
204. Jackson S, Harwood C, Thomas M, Banks L, Storey A. Role of BAK in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev. 2000;14:3065-3073.
205. Underbrink M, Howie H, Bedard K, Koop J, Galloway D. E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. J Virol. 2008;82: 10408-10417.
206. Kim H, Guo W, Park N. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways. Oncol Rep. 2000;7:707-712.
207. Magal S, Jackman A, Pei X, Schlegel R, Sherman L. Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both E6 and E7 oncoproteins. Int J Cancer. 1998;75:96-104.
208. Song S, Gulliver G, Lambert P. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A. 1998;95:2290-2295.
209. Shah K. Do human papillomavirus infections cause oral cancer? J Natl Cancer Inst. 1998;90:1585-1586.
210. Iftner T, Elbel M, Schopp B, Hiller T, Loizou J, Caldecott K, Stubenrauch F. Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBOJ. 2002;21:4741-4748.
211. Schiffman M, Kjaer S. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Mongr. 2003;31:14-19.
212. Tay S, Ho T, Lim-Tan S. Is genital human papillomavirus infection always sexually transmitted? Aust N Z J Obstet Gynaecol. 1990;30:240-242.
213. Howley P, Münger K. Human papillomaviruses and squamous cell carcinomas. In: Parsonnet J, editor. Microbes and Malignancy: Infection as a Cause of Human Cancers. New York: Oxford University Press, 1999: 157-179.
214. Arends M, Wyllie A, Bird C. Papillomaviruses and human cancer. Human Pathol. 1990;21:686-698.
215. Holly E, Ralston M, Darragh T, Greenblatt R, Jay N, Palefsky J. Prevalence and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst. 2001;93:843-849.
216. Palefsky J, Holly E, Ralston M, Da Costa M, Greenblatt R. Prevalence and risk factors for anal and human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis. 2001;183:383-391.
217. Palefsky J. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women. Semin Oncol. 2000;27:471-479.
218. Palefsky J, Holly E. Chapter 6: Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr. 2003;31:41-46.
219. Gillison M, Shah K. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr. 2003;31:57-65.
220. Fairley C, Chen S, Tabrizi S, et al. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysisdependent patients and patients with renal impairment. Nephrol Dial Transplant. 1994;9:416-420.
221. Moscicki A, Ellenberg J, Vermund S, et al. Prevalence of risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus. Arch Pediatr Adolesc Med. 2000;154:127-134.
222. Jamieson D, Duerr A, Burk R, et al. HIV Epidemiology Research Study (HERS) Group. Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol. 2002;186:21-7.
223. Sun X, Kuhn L, Ellerbrock T, Chiasson M, Bush T, Wright T. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med. 1997;337:1343-1349.
224. Frisch M, Biggar R, Goedert J. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-1510.
225. Palefsky J. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr. 1999;21:S42-S48.
226. Melbye M, Palefsky J, Gonzales J, et al. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer. 1990;46:203-206.
227. World Health Organization, International Agency for Research on Cancer. Human papillomavirus. IARC Monogr Eval Carcinog Risk Hum. 2007;90:1-670.
228. Ley C, Bauer H, Reingold A, et al. Determinants of genital human papillomavirus infectin in young women. J Natl Cancer Inst. 1991;83:997-1003.
229. World Health Organization, International Agency for Research on Cancer. Human papillomavirus. IARC Monogr Eval Carcinog Risk Hum. 1995;64:1-409.
230. Davidson M, Schnitzer P, Bulkow L, et al. The prevalence of cervical infection with human papillomaviruses and cervical dysplasia in Alaskanative women. J Infect Dis. 1994;169:792-800.
231. Karlsson R, Jonsson M, Edlund K, et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population- based study. Sex Transm Dis. 1995;22:119-127.
232. Burk R, Ho G, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174:679-689.
233. Schneider A. Pathogenesis of genital HPV infection. Genitourin Med. 1993;69:165-173.
234. Dillner J, Kallings I, Brihmer C, et al. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. J Infect Dis. 1996;173:1394-1398.
235. Winer R, Lee S, Hughes J, Adam D, Kiviat N, Koutsky L. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
236. Hildesheim A, Gravitt P, Schiffman M, et al. Determinants of genital human papillomavirus infection in low-income women in Washington, DC. Sex Transm Dis. 1993;20:279-285.
237. Wheeler C, Parmenter C, Hunt W, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis. 1993;20:286-289.
238. Bleeker M, Hogewoning C, Berkhof J, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis. 2005;41:612-620.
239. Baken L, Koutsky L, Kuypers J, et al. Genital human papillomavirus infection among male and female sex partners: prevalence and type-specific concordance. J Infect Dis. 1995;171:429-432.
240. Kyo S, Inoue M, Koyama M, Fujita M, Tanizawa O, Hakura A. Detection of high-risk papillomavirus in the cervix and semen of sex partners. J Infect Dis. 1994;170:682-685.
241. Strand A, Rylander E, Wilander E, Zehbe I. HPV infection in male partners of women with squamous intraepithelial neoplasia and/or high-risk HPV. Acta Derm Venereol. 1995;75:312-316.
242. Hippeläinen M, Yliskoski M, Syrjänen S, et al. Low concordance of genital human papillomavirus (HPV) lesions and viral types in HPV- infected women and their male sexual partners. Sex Transm Dis. 1994;21: 76-82.
243. Gerberding J. Prevention of Genital Human Papillomavirus Infection. Centers for Disease Control, Report to Congress, January 2004, pp 1-35.
244. Ho G, Burk R, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87:1365-1371.
245. Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158:486-494.
246. Schlecht N, Platt R, Duarte-Franco E, et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst. 2003;95:1336-1343.
247. Hernandez B, Wilkens L, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emer Infect Dis. 2008;14:888-894.
248. Plasmeijer E, Green A, de Koning M, et al. Transmission of betapapillomaviruses between domestic partners in an Australian community. J Clin Virol. 2010;47:216-218.
249. Moy R, Eliezri Y. Significance of human papillomavirus-induced squamous cell carcinoma to dermatologists. Arch Dermatol. 1994;130:235-238.
250. Ferenczy A, Bergeron C, Richart R. Human papillomavirus DNA in fomites on objects used for the management of patients with genital human papillomavirus infections. Obstet Gynecol. 1989;74:950-954.
251. Kjaer S, van den Brule A, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br Med J. 2002;325:572-578.
252. Nobbenhuis M, Walboomers J, Helmerhorst T, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervicalcancer screening: a prospective study. Lancet. 1999;354:20-25.
253. Remmink A, Walboomers J, Helmerhorst T, et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 1995;61:306-311.
254. Liaw K, Hildesheim A, Burk R, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001;183:8-15.
255. Brisson J, Bairati I, Morin C, et al. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis. 1996;173:794-799.
256. Woodman C, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357:1831-1836.
257. Ho G, Bierman R, Beardsley L, Chang C, Burk R. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
258. Moscicki A, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
259. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population- based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol. 2000;183:561-567.
260. Van Duin M, Snijders P, Schrijnemakers H, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer. 2002;98:590-595.
261. Hildeheim A, Schiffman M, Gravitt P, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
262. Tyring S. Human papillomavirus infections: epidemiology, pathogenesis,and host immune response. J Am Acad Dermatol. 2000;43:S18-S26.
263. Sellors J, Karwajtys T, Kaczorowski J, et al. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ. 2002;167:871-83.
264. Wang S, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a populationbased cohort of 10,000 women in Costa Rica. Br J Cancer. 2004;91: 1269-1274.
265. Jacobs M, Walboomers J, Snijders P, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000;87:221-227.
266. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002;87:324-333.
267. Kjaer S, van den Brule A, Bock J, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev. 1997;6:799-805.
268. Antonsson A, Erfurt C, Hazard K, et al. Prevalence and type spectrum of human papillomaviruses in healthy skin samples collected in three continents. J Gen Virol. 2003;84:1881-1886.
269. Hsu J, Chen A, Keleher A, McMillan N, Antonsson A. Shared and persistent asymptomatic cutaneous human papillomavirus infections in healthy skin. J Med Virol. 2009;81:1444-1449.
270. Weissenborn S, de Koning M, Wieland U, Quint W, Pfister H. Intrafamilial transmmission of family-specific spectra of cutaneous betapapillomaviruses. J Virol. 2009;83:811-816.
271. Berkhout R, Bouwes Bavinck J, Ter Schegget J. Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. J Clin Microbiol. 2000;38:2087-2096.
272. Hazard K, Karlsson A, Andersson K, Ekberg H, Dillner J, Forslund O. Cutaneous human papillomaviruses persist on healthy skin. J Invest Dermatol. 2007;127:116-119.
273. Boxman I, Berkhout R, Mulder L, et al. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol. 1997;108:712-715.
274. Boxman I, Hogewoning A, Mulder L, Bouwes Bavinck J, ter Schegget J. Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. J Clin Microbiol. 1999;37:2270-2273.
275. Wolf P, Seidl H, Bäck B, et al. Increased prevalence of human papillomavirus in hairs plucked from patients with psoriasis treated with psoralen- UV-A. Arch Dermatol. 2004;140:317-324.
276. Boxman I, Russell A, Mulder L, Bouwes Bavinck J, ter Schegget J, Green A. Case-control study in a subtropical Australian population to assess the relation between non-melanoma skin cancer and epidermodysplasia verruciformis human papillomavirus DNA in plucked eyebrow hairs.The Nambour Skin Cancer Prevention Study Group. Int J Cancer. 2000;86:118-121.
277. Weissenborn S, Höpfl R, Weber F, Smola H, Pfister H, Fuchs P. High prevalence of a variety of epidermodysplasia verruciformis-associated human papillomaviruses in psoriatic skin of patients treated or not treated with PUVA. J Invest Dermatol. 1999;113:122-126.
278. Chen A, McMillan N, Antonsson A. Human papillomavirus type spectrum in normal skin of individuals with or without a history of frequent sun exposure. J Gen Virol. 2008;89:2891-2897.
279. Forslund O, Iftner T, Andersson K, et al. Cutaneous human papillomaviruses found in sun-exposed skin: beta-papillomavirus species 2 predominatesin squamous cell carcinoma. J Infect Dis. 2007;196:876-883.
280. Waterboer T, Neale R, Michael K, et al. Antibody responses to 26 skin human papillomavirus types in the Netherlands, Italy and Australia. J Gen Virol. 2009;90:1986-1998.
281. Barbosa M, Vass W, Lowy D, Schiller J. In vitro biological activities of E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. J Virol. 1991;65:292-298.
282. Storey A, Osborn K, Crawford L. Co-transformation by human papillomavirus types 6 and 11. J Gen Virol. 1990;71:165-171.
283. Ostrow R, Bender M, Niimura M, et al. Human papillomavirus DNA in cutaneous primary and metastasized squamous cell carcinomas from patients with epidermodysplasia verruciformis. Proc Natl Acad Sci U S A. 1982;79:1634-1638.
284. Harwood C, Surentheran T, McGregor J, et al. Human papillomavirus infectin and non-melanoma skin cancer immunosuppressed and immunocompetent individuals. J Med Virol. 2000;61:289-297.
285. Majewski S, Jablonska S. Do epidermodysplasia verruciformis human papillomaviruses contribute to malignant and benign epidermal proliferations? Arch Dermatol. 2002;138:649-654.
286. Tommasino M, Pawlita M. Epidermodysplasia verruciformis (EV) human papillomavirus types: co-factors in skin carcinogenesis beyond EV? Papillomavirus Report. 2004;15:337-3378.
287. Orth G. Epidermodysplasia verruciformis. In: Salzman N, Howley P, editors. The Papovaviridae: The Papillomaviruses. New York: Plenum Publishing Corp. 1987;2:199-243.
288. De Jong-Tieben L, Berkhout R, Smits H, et al. High frequency of detection of epidermodysplasia verruciformis-associated human papillomavirus DNA in biopsies from malignant and premalignant skin lesions from renal transplant recipients. J Invest Dermatol. 1995;105:367-371.
289. Surentheran T, Harwood C, Spink P, et al. Detection and typing of human papillomaviruses in mucosal and cutaneous biopies from immunosuppressed and immunocompetent patients and patients with epidermodysplasia verruciformis: a unified diagnostic approach. J. Clin Path. 1998;51:606-610.
290. Birkeland S, Storm H, Lamm L, et al. Cancer risk after renal transplantation in the nordic countries, 1964-1986. Int J Cancer. 1995;60:183-189.
291. Hartevelt M, Bavinck J, Kootte A, Vermeer B, Vanderbroucke J. Incidence Of skin cancer after renal transplantation in The Netherlands. Transplantation. 1990;49:506-509.
292. Hardie I, Strong R, Hartley L, Woodruff P, Clunie G. Skin cancer in Caucasian renal allograft recipients living in a subtropical climate. Surgery. 1980;87:177-183.
293. Walder B, Robertson M, Jeremy D. Skin cancer and immunosuppression. Lancet. 1971;21:1282-1283.
294. Kinlen L, Sheil A, Peto J, Doll R. Collaborative United Kingdom- Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med. 1979;2:1461-1466.
295. Wu X, Nguyen B, Dziunycz P, et al. Opposing roles for calcineurin and ATF3 in squamous skin cancer. Nature. 2010;465:368-372.
296. Salgo R, Grossman J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant. 2010;10:1385-1393.
297. Iftner A, Klug S, Garbe C, et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res. 2003;63:7515-7519.
298. De Villiers E, Lavergne D, McLaren K, Benton E. Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. Int J Cancer. 1997;73:356-361.
299. Blessing K, McLaren K, Benton E, et al. Histopathology of skin lesions in renal allograft recipients-an assessment of viral features and dysplasia. Histopathology. 1989;14:129-139.
300. Goldberg L, Griego R. Absence of human papillomavirus in squamous cell carcinomas of nongenital skin from immunocompromised renal transplant patients: a comment. Arch Dermatol. 1995;131:107-108.
301. Asgari M, Kiviat N, Critchlow C, et al. Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. J Invest Dermatol. 2008;128:1409-1417.
302. Forslund O, Lindelöf B, Hradil E, et al. High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "stripped" biopsies from the same tumors. J Invest Dermatol. 2004;123:388-394.
303. Feltkamp M, Broer R, di Summa F, et al. Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res. 2003;63:2695-2700.
304. Karagas M, Nelson H, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst. 2006;98:389-395.
305. Hall L, Struijk L, Neale R, Feltkamp M. Re: human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst. 2006;98:1425-1426.
306. Baseman J, Koutsky L. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32S:S16-S24.
307. Ho G, Studentsov Y, Bierman R, Burk R. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev. 2004;13:110-116.
308. Carter J, Koutsky L, Wipf G, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis. 1996;174:927-936.
309. Harwood C, Surentheran T, Sasieni P, et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol. 2004;150:949-957.
310. Struijk L, Bouwes Bavinck J, Wanningen P, et al. Presence of human papillomavirus DNA in plucked eyebrow hairs is associated with a history of cutaneous squamous cell carcinoma. J Invest Dermatol. 2003;121:1531-1535.
311. Arends M, Benton E, McLaren K, Stark L, Hunter J, Bird C. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer. 1997;75:722-728.
312. Levi F, Randimbison L, Te V, La Vecchia C. Nonmelanomatous skin cancer following cervical, vaginal, and vulvar neoplasms: etiologic association. J Natl Cancer Inst. 1998;90:1570-1571.
313. Hemminki K, Dong C, Vaittinen P. Secondary primary cancer after in situ and invasive cervical cancer. Epidemiology. 2000;11:457-461.
314. Hemminki K, Jiang Y, Steineck G. Skin cancer and non-Hodgkin's lymphoma as second malignancies: markers of impaired immune function? Eur J Cancer. 2003;39:223-229.
315. Majewski S, Jablonska S. Current views on the role of human papillomaviruses in cutaneous oncogenesis. Int J Dermatol. 2006;45:192-196.
316. Skinner G. Transformation of primary hamster embryo fibroblasts by type 2 simplex virus: evidence for a "hit and run" mechanism. Br J Exp Path. 1976;57:361-376.
317. Weissenborn S, Nindl I, Purdie K, et al. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. J Invest Dermatol. 2005;125:93-97.
318. Nevels M, Täuber B, Spruss T, Wolf H, Dobner T. Hit-and Run" transformation by adenovirus oncogenes. J Virol. 2001;75:3089-3094.
319. Bouwes Bavinck J, Plasmeijer E, Feltkamp M. ß-Pappillomavirus infection and skin cancer. J Infect Dis. 2008;128:1355-1358.
320. Schaper I, Marcuzzi G, Weissenborn S, et al. Development of skin tumors in mice transgenic for early genes of human papillomavirus type 8. Cancer Res. 2005;65:1394-1400.
321. Moscicki A, Schiffman M, Kjaer S, Villa L. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24:S3/42-51.
322. Steger G, Pfister H. In vitro expressed HPV 8 E6 protein does not bind p53. Arch. Virol. 1992;125:355-360.
323. Tommasino M, Accardi R, Caldeira S, Dong W, et al. The role of TP53 in cervical carcinogenesis. Hum Mutat. 2003;21:307-312.
324. Tibbetts T, Conneely O, O'Malley B. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus. Biol Reprod. 1999;60:1158-1165.
325. Gravitt P, Hildesheim A, Herrero R, et al. Correlates of IL-10 and IL 12 concentrations in cervical secretions. J Clin Immunol. 2003;23:175-183.
326. Clerici M, Shearer G, Clerici E. Cytokine dysregulation in invasive cervical carcinoma and other human neoplasias: time to consider the TH1/TH2 paradigm. J Natl Cancer Inst. 1998;90:261-263.
327. Franklin R, Kutteh W. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol. 1999;42:93-106.
328. Wira C, Sandoe C. Specific IgA and IgG antibodies in the secretions of the female reproductive tract: effects of immunization and estradiol on expression of this response in vivo. J Immunol. 1987;138:4159-4164.
329. Moreno V, Bosch F, Muñoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359:1085-1192.
330. Moscicki A, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285:2995-3002.
331. Stanko C, Weitzen S, Sung C. Atypical squamous cells of undetermined significance: human papillomavirus testing in adolescents. Obstet Gynecol. 2005;105:741-746.
332. Stone K, Karem K, Sternberg M, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis. 2002;186:1396-1402.
333. Schneider A, Hotz M, Gissmann L. Increased prevalence of human papillomaviruses in the lower genital tract of pregnant women. Int J Cancer. 1987;40:198-201.
334. Wang S, Schiffman M, Shields T, et al. Seroprevalence of human papillomavirus 16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer. 2003;89:1248-1254.
335. Negrini B, Schiffman M, Kurman R, et al. Oral contraceptive use, human papillomavirus infection, and risk of early cytological abnormalities of the cervix. Cancer Res. 1990;50:4670-4675.
336. Mitrani-Rosenbaum S, Tsviel R, Tur-Kaspa R. Oestrogen stimulates differential transcription fo human papillomavirus type 16 in Si Ha cervical carcinoma cells. J Gen Virol. 1989;70:2227-2232.
337. Gloss B, Bernard H, Seedorf K, Klock G. The upstream regulatory region of the human papilloma virus-16 contains an E2 protein-independent enhancer which is specific for cervical carcinoma cells and regulated by glucocorticoid hormones. EMBOJ. 1987;6:3735-3743.
338. Pater M, Hughes G, Hyslop D, Nakshatri H, Pater A. Glucocorticoid- Dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature. 1988;335:832-835.
339. Chan W, Klock G, Bernard H. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia. J Virol. 1989;63:3261-3269.
340. Arbeit J, Howley P, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci. 1996;93:2930-2935.
341. Castellsagué X, Muñoz N. Chapter3: cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;31:20-28.
342. Naib A, Nahmias A, Josey W. Cytology and histopathology of cervical herpes simplex infection. Cancer. 1966;19:1026-1031.
343. Garris L, Steckler A, McIntire J. The relationship between oral contraceptives and adolescent sexual behavior. J Sex Res. 1976;12:135-146.
344. Abma J, Martinez G, Mosher W, Dawson B. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat. 2004;23:1-48.
345. Herbst A, Ulfelder H, Poskanzer D. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med. 1971;284:878-881.
346. Chen J, Fleischer A, Smith E, et al. Cost of nonmelanoma skin cancer treatment in the United States. Dermatol Surg. 2001;27:1035-1038.
347. Housman T, Feldman S, Williford P, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425-429.
348. Wheless L, Black J, Alberg A. Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review. Cancer Epidemiol Biomarkers Prev. 2010;19;1686-1695.
349. Rogers H, Weinstock M, Harris A, et al. Incidence estimates of nonmelanoma skin in the United States, 2006. Arch Dermatology. 2010;146:283-287.